CAMBRIDGE, England, July 26, 2016 /PRNewswire/ --
Inivata, a global clinical cancer genomics company employing the precision of circulating tumour DNA (ctDNA) analysis to improve personalised healthcare in oncology, has appointed Dr Peter Wrighton-Smith to its Board of Directors. Dr Wrighton-Smith brings strategic product development and international commercialisation experience to Inivata's Board along with a broad understanding of the clinical service testing market.
Dr Wrighton-Smith is the Chief Executive Officer and Founder of Oxford Immunotec Global PLC, a high-growth global diagnostics company focussing on monitoring immune-regulated conditions. Peter has led Oxford Immunotec from the foundation stages, through product development to regulatory approval in over 50 countries, and subsequent worldwide commercialisation via both a kit and a CLIA lab model. Over that time, Oxford Immunotec has raised five rounds of venture funding prior to an IPO on NASDAQ in 2013. Dr Wrighton-Smith has a Masters in Engineering, Economics and Management, and a Doctorate in Medical Engineering, both from University of Oxford.
"Peter's strong leadership and commercialisation experience in both the US and UK will further strengthen the Inivata Board as we move towards the launch of InVision®," said Jeffrey H. Buchalter, Chairman of the Board, Inivata.
Peter Wrighton-Smith said, "Inivata's liquid biopsy platform, InVision, has enormous potential. Their demonstrated best-in-class sensitivity and strategically selected gene panel to target actionable mutations for clinicians promises to revolutionise oncologists' ability to assess and treat their patients."
Inivata's molecular profiling utilises a robust and reproducible platform exhibiting the highest sensitivity and specificity for the detection of genomic alterations in ctDNA. eTAm-Seq profiling of clinical samples has revealed the detection of mutations at frequencies that may be missed by less sensitive assays. The analytical validation of InVision presented at AACR in 2016 supports its use in prospective clinical studies to demonstrate the clinical validation and utility in using ctDNA analysis for precision medicine applications particularly for patients where tumour tissue is limited or unavailable. Peter Wrighton-Smith's experience and expertise in international clinical service testing and commercialisation will further advance Inivata's liquid biopsy initiatives.
Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalised healthcare in oncology. Using a simple blood test, circulating tumour DNA (ctDNA) analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata's proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata's InVision® ctDNA assay provides a highly sensitive analysis of a strategically selected gene panel to identify actionable mutations for oncologists to treat their patients optimally. For more information and a full listing of investors, please go to http://www.inivata.com . Follow us on Twitter @Inivata
Phone: +44 (0)7739462323
Consilium Strategic Communications
Chris Gardner/Laura Thornton
Phone: +44 (0)20 3709 5700